Anterogen Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from a group of investors.
June 11, 2018
Share
Anterogen Co.,Ltd. (KOSDAQ:A065660) announced a private placement of 3rd series unregistered unguaranteed and unsecured private convertible bonds for gross proceeds of KRW 16,000,000,000 on June 11, 2018. The bonds are issued at zero interest rate and will mature on June 12, 2020. The bonds can be 100% converted into 113,797 common shares for 1.41% stake of the company at a fixed conversion price of KRW 140,601 per share. The conversion period is from June 12, 2019 to May 28, 2020. The transaction will include participation from HR DaVinci Venture Capital Hedge Fund 2 for KRW 4,000,000,000, TL Venture Capital Hedge Fund 1 for KRW 3,500,000,000, Golden Key Bonanza Venture Capital Hedge Fund 1 for KRW 2,000,000,000 and other investors. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 12, 2018.
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.